Last reviewed · How we verify
liposomal irinotecan monotherapy
At a glance
| Generic name | liposomal irinotecan monotherapy |
|---|---|
| Sponsor | Dong sheng Zhang |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (PHASE2)
- Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy (PHASE1, PHASE2)
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (PHASE3)
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial (PHASE2)
- Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies (PHASE2)
- Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients (PHASE2)
- A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- liposomal irinotecan monotherapy CI brief — competitive landscape report
- liposomal irinotecan monotherapy updates RSS · CI watch RSS
- Dong sheng Zhang portfolio CI